A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most common malignances seen in different
regions of the world. The 5-year risk of recurrence of HCC after resection has been reported
to be as high as 70%. It has been proposed that best way to reduce recurrence is to search
for improved adjuvant therapies. Especially for some postoperative patients who were
identified with the risk factors for recurrence, several adjuvant therapies were often used,
including TACE. Recently, a variety of Traditional Chinese Medicine combined with TACE for
toxicity reduction and enhancing the efficacy have been investigated in the treatment of HCC.
Cidan capsules are a formula containing more than ten types of plant extracts, and has been
clinically used for >10 years as a safe and nontoxic antitumor drug. However, the safy and
efficacy of preventive therapy is still not clear. In this prospective control study, we
enroll such HCC patients experienced operation and were identifed with high risk of
recurrence. After a preventive TACE, the eligible patients were divided into two groups. One
group will accept Cidan therapy and another will not. Under a basis of large sample, the
safty and efficacy of Cidan combined with TACE in HCC patients will be investigated and
analysed.